Scoopfeeds — Intelligent news, curated.
Alexion gets FDA priority review for Ultomiris in rare kidney disease
business

Alexion gets FDA priority review for Ultomiris in rare kidney disease

Investing.com · Jun 15, 2026, 6:18 AM

Alexion gets FDA priority review for Ultomiris in rare kidney disease

Read full story on Investing.com → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop